Cannabis use, harms and the management of cannabis use disorder

Neuropsychiatry

Volumn 4, Issue 1, 2014, Pages 55-63

  Copeland, Jan ^a   Clement, Nicole ^a   Swift, Wendy ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANANDAMIDE; ANANDAMINE; ATOMOXETINE; BUSPIRONE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ILLICIT DRUG; LOFEXIDINE; NABIXIMOLS; NEFAZODONE; NICOTINE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM;

BEHAVIOR CHANGE; BEHAVIOR THERAPY; CANNABIS ADDICTION; CANNABIS USE DISORDER; CLINICAL ASSESSMENT; CONTINGENCY MANAGEMENT; COPING BEHAVIOR; DISEASE SEVERITY; DRUG EFFICACY; DRUG SEEKING BEHAVIOR; DSM-5; EARLY DIAGNOSIS; EMPATHY; HUMAN; ICD-10; INTOXICATION; LEARNING DISORDER; MEMORY DISORDER; MENTAL DISEASE; MENTAL HEALTH; MOTIVATION; MOTIVATIONAL ENHANCEMENT THERAPY; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DENSITY; RESPIRATORY TRACT DISEASE; REVIEW; SCREENING; SOCIAL DISABILITY; SUBSTANCE ABUSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

EID: 84893187159     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.13.90     Document Type: Review

References (95)

1. United Nations Office of Drugs and Crime. World Drug Report. United Nations Publications, NY, USA (2013).
2. Australian Institute of Health and Welfare. 2010 National Drug Household Survey Report. Australian Institute of Health and Welfare, Canberra, Australia (2011).
3. European Monitoring Centre for Drugs and Drugs Addiction European Drug Report; Trends and Developments European Monitoring Centre for Drugs and Drugs Addiction, Lisbon, Portugal 2013
4. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Results from the National Survey on Drug Use and Health; Summary of National Findings. Substance
5. Abuse and Mental Health Services Administration, MD, USA (2012).
6. Agrawal A, Sartor CE, Lynskey MT et al. Evidence for an interaction between age at first drink and genetic influences on DSM-IV alcohol dependence symptoms. Alcohol Clin. Exp. Res. 33(12), 2047-2056 (2009).
7. Degenhardt L, Chiu WT, Sampson N et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO world mental health surveys. PLoS Med. 5(7), 1053-1067 (2008).
8. Beavaris F, Jumper-Thurman P, Helm H, Plested B, Burnside M. Surveillance of drug use among American-Indian adolescents; patterns over 25 years. J. Adolescent Health 34, 393-500 (2004).
9. Lee K, Conigrave KM, Clough AR, Dobbins TA, Jaraqba MJ, Patton GC. Five year longitudinal study of cannabis users in three remote Aboriginal communities in Arnhem Land, Northern Territory Australia. Drug Alcohol Rev. 28(6), 623-630 (2009).
10. Clough AR, Lee KSK, Cairney S et al. Changes in cannabis use and its consequences over 3 years in a remote indigenous population in northern Australia. Addiction 101(5), 696-705 (2006).
11. Stinson FS, Ruan WJ, Pickering RP, Grant BF. Cannabis use disorders in the USA; prevalence, correlates and comorbidity. Psychol. Med. 36, 1447-1460 (2006).
12. Anthony J. The epidemiology of cannabis dependence. In: Cannabis Dependence; Its Nature, Consequences and Treatment. Roffman RA, Stephens RS (Eds). Cambridge University Press, Cambridge, UK, 58-105 (2006).
13. Rosenberg MF, Anthony JC. Early clinical manifestations of cannabis dependence in a community sample. Drug Alcohol Depend. 64, 121-131 (2001).
14. Degenhardt L, Hall WD, Lynskey M, McGrath J, Calabria B. Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med. 6(9), e10000133 (2009).
15. Degenhardt L, Whiteford HA, Ferrari J et al Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. Lancet 382(9904), 1564-1574, (2013).
16. Lorenzetti N, Solowij N, Fornito A, Lubman D, Yucel M. The association between regular cannabis exposure and alterations of human brain morphology: An updated review of the literature. Curr. Pharm. Des. doi:10.2174/138 16128113199990435 (2013) (Epub ahead of print).
17. Solowij N. Cannabis and Cognitive Functioning. Cambridge University Press, Cambridge, UK (1998).
18. Meier MH, Avshalom C, Ambler A et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl Acad. Sci. USA 109(40), E2657-E2664 (2012).
19. Tashkin DP. Cannabis effects on the respiratory system. In: The Health Effects of Cannabis. Kalant H, Corrigall W, Hall W, Smart R (Eds). Centre for Addiction Medicine, Toronto, ON, Canada, 311-346 (1999).
20. Taylor D, Fergusson DM, Milne B et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction 97(8), 1055-1061 (2002).
21. Moore BA, Ayugustson EM, Moser RP, Budney A. Respiratory effects of marijuana and tobacco use in a U.S sample. J. Gen. Intern. Med. 20, 33-37 (2004).
22. Mouzak A, Agathos P, Kerezoudi E, Mantas A, Vourdeli-Yiannakoura E. Transient ischemic attack in heavy cannabis smokers-how 'safe' is it? Eur. Neurol. 44, 42-44 (2000).
23. Ford DE, Hong TV, James CA. Marijuana use and cessation of tobacco smoking in adults from a community sample. Drug Alcohol Depend. 67(3), 243-248 (2002).
24. Amos A, Wiltshire S, Bostock Y, Haw S, McNeill A. 'You can't go without a fag you need it for your hash' a qualitative exploration of smoking, cannabis and young people. Addiction 99(1), 77-81 (2003).
25. Blows S, Ivers R, Connor JP, Ameratunga S, Woodward M, Norton R. Marijuana use and car crash injury. Addiction 100(5), 605-611 (2005).
26. Drummer O, Gerostamoulos J, Batziris H et al. The involvement of drugs in drivers of motor vehicle killed in Australian road traffic crashes. Accid. Anal. Prev. 36(2), 239-248 (2004).
27. Wadsworth EJ, Moss SC, Simpson SA, Smith AP. A community based investigation of the association between cannabis use, injuries and accidents. J. Psychopharmacol. 20(1), 5-13 (2006).
28. McLaren J, Mattick RP Cannabis Use in Australia: Use, Supply, Harms and Responses. Mongraph no 57. Drug Strategy Branch, Australian Government Department, of Health and Ageing, Canberra, Australia (2006).
29. Budney AJ, Moore BA. Development and consequences of cannabis dependence. J. Clin. Pharmacol. 42(11 Suppl.), S28-S33 (2002).
30. D'Souza D, Sewell R, Ranganathan M. Cannabis and psychosis/schizophrenia: Human studies. Euro. Arch. Psychiatry Clin. Neurosci. 259(7), 413-431 (2009).
31. Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use, depression and anxiety among Australian adults: Findings from the National Survey of Mental Health and Well-Being. Social Psychiatry Psychiatr. Epidemiol. 36(5), 219-227 (2001).
32. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: Results of a national survey of adults. J. Substance Abuse 7, 481-497 (1995).
33. Chen CY, Wagner F, Anthony J. Marijuana use and the risk of major depressive episode: Epidemiological evidence from the United States National Comorbidity Survey. Social Psychiatry Psychiatr. Epidemiol. 37, 199-206 (2002).
34. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M. Mental health of teenagers who use cannabis: Results of an Australian survey. Br. J. Psychiatry 180, 216-221 (2002).
35. Horwood LJ, Fergusson DM, Hayatbakhsh MR et al. Cannabis use and educational achievement: Findings from three Australasian cohort studies. Drug Alcohol Depend. 110(3), 247-253 (2010).
36. Lev-Ryan S, Roercecke M, Lefoll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: A systematic review and meta-Analysis of longitudinal studies. Psychol. Med. 24, 1-14 (2013).
37. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction 98(11), 1493-1504 (2003).
38. Wilcox HC, Anthony JC. The development of suicide ideation andattempts: An epidemiologic study of first graders followed into young adulthood. Drug Alcohol Depend. 76(Suppl.), S53-S67 (2004
39. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97(9), 1123-1135 (2002
40. Degenhardt L, Coffey C, Romaniuk H et al. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 108(1), 124-133 (2013
41. Swift W, Hall W, Copeland J. One year follow-up of cannabis dependence among long-Term users in Sydney, Australia. Drug Alcohol Depend. 59(3), 309-318 (2000
42. Hingson R, Alpert JJ, Day N. Effects of maternal drinking and marijuana use on fetal growth and development. Pediatrics 70(4), 539-546 (1982
43. Sherwood RA, Keating J, Kavvadia V, Greenough A, Peters TJ. Substance misuse in early pregnancy and relationship to fetal outcome. Eur. J. Pediatr. 158(6), 488-492 (1999
44. Klonoff-Cohen HS, Natarajan L, Chen RV. A prospective study of the effects of female and male marijuana use on in-vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) outcomes. Am. J. Obstetr. Gynecol. 194(2), 369-376 (2006
45. Fergusson DM, Horwood LJ, Lynskey MT, Madden PA. Early reactions to cannabis predict later dependence. Arch. Gen. Psychiatry 60(10), 1033-1039 (2003
46. Pridmore HM, Barber A, Anderson N, Spriggs D, Roberts S. Increased cannabis use in young stroke patients. J. Clin. Neurosci. 17(12), 1620 (2010
47. Fergusson DM, Horwood LJ, Beautrais AL. Cannabis and educational achievement. Addiction 98(12), 1681-1692 (2003
48. Andrews G, Hall W, Teesson M, Henderson S. The Mental Health of Australians. Mental Health Branch, Commonwealth Department of Health and Aged Care, Canberra, Australia (1999
49. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: A systematic meta-Analysis. Arch. Gen. Psychiatry 68(6), 555-561 (2011
50. Agrawal A, Lynskey MT, Bucholz KK et al.DSM-5 cannabis use disorder: A phenotypic and genomic perspective. Drug Alcohol Depend. 134, 362-369 (2014
51. Mewton L, Slade T, Teesson M. An evaluation of the proposed DSM-5 cannabis use disorder criteria using Australian national survey data. J. Stud. Alcohol Drugs 74(4), 614-621 (2013
52. Chung T, Colby SM, O'Leary TA, Barnett NP, Monti PM. Screening for cannabis use disorders in an adolescent emergency department sample. Drug Alcohol Depend. 70(2), 177-186 (2003
53. Allsop DJ, Copeland J, Norberg MM et al. Quantifying the clinical significance of cannabis withdrawal. PLoS One 7(9), e44864 (2012
54. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr. Opin. Psychiatry 19(3), 233-238 (2006
55. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J. Abnormal Psychol. 112(3), 393-402 (2003
56. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. J. Substance Abuse Treat. 20(1), 45-52 (2001
57. Copeland J, Swift W. Cannabis use disorder: Epidemiology and management. Int. Rev. Psychiatr. 21(2), 96-103 (2009
58. Copeland J, Gilmour S, Gates P, Swift W. The Cannabis Problems Questionnaire: Factor structure, reliability, and validity. Drug Alcohol Depend. 80(3), 313-319 (2005
59. Martin G, Copeland J, Gilmour S, Gates P, Swift W. The Adolescent Cannabis Problems Questionnaire (CPQ-A): Psychometric properties. Addict. Behav. 31(12), 2238-2248 (2006
60. Swift W, Copeland J, Hall W. Choosing a diagnostic cut-off for cannabis dependence. Addiction 93(11), 1681-1692 (1998
61. Martin G, Copeland J, Gates P, Gilmour S. The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: Reliability, validity and diagnostic cut-off. Drug Alcohol Depend. 83(1), 90-93 (2006
62. Bashford J, Flett R, Copeland J. The Cannabis Use Problems Identification Test (CUPIT): Development, reliability, concurrent and predictive validity among adolescents and adults. Addiction 105(4), 615-625 (2010
63. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 119(1-2), 123-129 (2011
64. Stephens RS, Roffman RA, Simpson EE.Adult marijuana users seeking treatment.J. Consult. Clin. Psychol. 61(6), 1100-1104(1993
65. Tirado CF, Goldman M, Lynch K, Kampman KM, O' Brien CP. Atomoxetine for treatment of marijuana dependence: A report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend. 94(1-3), 254-257 (2008
66. Hart JC. Increasing treatment options for cannabis dependence; a review of potential pharmacotherapies. Drug Alcohol Depend.80(2), 147-159 (2005
67. Roten AT, Baker NL, Gray KM. Marijuana craving trajectories in an adolecent cessation pharmacotherapy trial. Addict. Behav. 38(3), 1788-1791 (2013
68. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 197(1), 157-168 (2008
69. Gray KM, Carpenter MJ, Baker NL et al. A double blind randomised control trial of N-Acetyl cysteine in cannabis depdendent adolescents. Am. J. Psychiatr. 169(8), 805-812 (2012
70. Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: Two case reports and review. Am. J. Addict. 17(2), 161-164 (2008
71. Haney M, Hart CL, Vocburg SK et al. Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology 29(1), 158-170 (2004
72. Levin FR, Mariani JJ, Brook DJ, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: A randomised, double-blind, placebo-controlled trial. Drug Alcohol Depend. 116, 142-150 (2011
73. Allsop DJ, Copeland J, Lintzeris N. Cannabinoid replacement therapy for management of cannabis withdrawal; a randomised controlled trial of nabiximols. J. Am. Med. Assoc. (2014) (In press
74. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš LO. Cannabidiol-recent advances. Chem. Biodiversity 4(8), 1678-1692 (2007
75. Hayakawa K, Mishima K, Hazekawa M et al. Cannabidiol potentiates pharmacological effects of D9-Tetrahydrocannabinol via CB1 receptor-dependent mechanism. Brain Res. 1188, 157-164 (2008
76. Pertwee RGrfsti The diverse CB1 and CB2 receptor pharmacology of three plant
77. Crippa JA, Hallak JE, Machado-De-Sousa JP et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: A case report. J. Clin. Pharm. Therapeut. 38, 162-164 (2013).
78. Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of delta(9)-Tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35(9), 1879-1885 (2010).
79. Babor TF, Carroll K, Christiansen K et al. Brief treatments for cannabis dependence: Findings from a randomized multi-site trial. J. Consult. Clin. Psychol. 72(3), 455-466 (2004).
80. Stein LAR, Lebeau R, Colby SM, Barnett NP, Golembeske C, Monti PM. Motivational interviewing for incarcerated adolescents: Effects of depressive symptoms on reducing alcohol and marijuana use after release. J. Stud. Alcohol Drugs 72(3), 497-506 (2011).
81. Martin G, Copeland J, Swift W. The Adolescent Cannabis Check-Up: Feasibility of a brief intervention for young cannabis users. J. Substance Abuse Treat. 29(3), 207-213 (2005).
82. Walker DD, Roffman RA, Stephens RS, Berghuis H, Kim W. Motivational enhancement therapy for adolescent marijuana users: A preliminary randomised controlled trial. J. Consult. Clin. Psychol. 74(3), 628-632 (2006).
83. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J. Substance Abuse Treat. 21(2), 55-64; discussion 65-56 (2001).
84. Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: Findings from a randomised multi-site trial. J. Consult. Clin. Psychol. 72(3), 455-466 (2004).
85. Norberg MM, Wright T, Hickey K, Copeland J. A postal intervention for dependent cannabis users. Drug Alcohol Rev. 31(3), 320-326 (2012).
86. Gates PJ, Norberg MM, Copeland J, Digiusto E. Randomized controlled trial of a novel cannabis use intervention delivered by telephone. Addiction 107(12), 2149-2158 (2012).
87. Litt MD, Kadden KM, Petry N. Behavioral treatment for marijuana dependence: Randomised trial of contingency management and self-efficacy enhancement. Addict. Behav. 38(3), 1764-1775 (2013).
88. Sinha R, Easton C, Renee-Aubin L, Carroll KM. Engaging young probation-referred marijuana-Abusing individuals in treatment: A pilot trial. Am. J. Addict. 12(4), 314-323 (2003).
89. Sigmon SG, Steingard S, Badger GJ, Anthony SL, Higgins ST. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness; a feasibility study. Exper. Clin. Psychopharmacol. 8(4), 509-517 (2000).
90. Rooke SE, Copeland J, Norberg M, Hine D, McCambridge J. Randomised controlled trial of 'reduce your use': A self-guided web-based cannabis treatment program. J. Med. Internet Res. 14, e26 (2012).
91. Budney AJ, Fearer S, Walker DD et al. An initial trial of a computerised behavioral intervention for cannabis use disorder. Drug Alcohol Depend. 115(1-2), 74-79 (2011).
92. Liddle HA, Dakof GA, Turner RM, Henderson CE, Greenbaum PE. Treating adolescent drug abuse: A randomized trial comparing multidimensional family therapy and cognitive behavior therapy. Addiction 103(10), 1660-1670 (2008).
93. Dennis M, Godley SH, Diamond G et al. Main findings of the cannabis youth treatment (CYT) randomized field experiment. J. Addict. Dis. 21(2), 111 (2002).
94. Bujarski SJ, Norberg MM, Copeland J. The association between distress tolerance and cannabis use-related problems: The mediating and moderating roles of coping motives and gender. Addict. Behav. 37(10), 1181-1184 (2012).
95. Rooke SE, Norberg MM, Copeland J. Successful and unsuccessful cannabis quitters: Comparing group characteristics and quitting strategies. Subst. Abuse Treat. Prev. Policy 6, 30 (2011).